跳到正文
原文
MedTech Dive 器械媒体· Susan Kelly·· 22 天前精选AI 评分75

Abbott 的 Amplatzer Paraclose 封堵器获 FDA 批准用于治疗瓣周漏

Abbott grows cardiac portfolio with Amplatzer approval for valve leaks

AI 导读

Abbott 的 Amplatzer Paraclose PVL Occluder 获 FDA 批准,用于经导管封堵外科换瓣术后的瓣周漏。该器械经腿部血管置入,为患者提供再次开胸手术之外的微创选择;Abbott 称瓣周漏在二尖瓣置换中发生率 7%–17%、主动脉瓣置换中 5%–10%。批准基于 PARADIGM 前瞻性多中心单臂研究 200 例患者的数据,30 天结果将在 TCT 大会公布。

推荐理由

FDA 批准 Abbott 的经导管封堵器用于瓣周漏,为外科换瓣术后患者提供再次开胸之外的介入选择。

正文

An article from site logo

Dive Brief

The first-of-its-kind transcatheter device treats paravalvular leak after valve replacement surgery, to spare the patient from another open-heart surgery.

Published Oct. 29, 2026

By

An image of an oval blue medical device.

Abbott's Amplatzer Paraclose PVL Occluder is designed to close leaks around surgical replacement heart valves. Permission granted by Abbott

This audio is auto-generated. Please let us know if you have feedback.

Dive Brief:

  • Abbott said Wednesday it received Food and Drug Administration approval for a transcatheter device designed to close a small gap that can develop between the heart tissue and a new valve after replacement surgery, causing blood to leak.
  • Such paravalvular leaks occur in 7% to 17% of mitral valve replacements and 5% to 10% of aortic valve replacements, the company said.
  • The Amplatzer Paraclose PVL Occluder is the first minimally invasive device approved in the U.S. to close paravalvular leaks around surgical replacement heart valves and offers an alternative to additional open-heart surgery for addressing the problem.

Dive Insight:

Paravalvular leaks can cause shortness of breath, swelling of the legs and feet, and damage to red blood cells, according to Abbott. 

The Amplatzer Paraclose device, implanted with a catheter delivered through an artery or vein in the leg, fills a critical unmet need that allows many patients to avoid the risks of another surgery, Sandra Lesenfants, senior vice president of Abbott’s structural heart business, said in a statement.

FDA approval for the device was supported by positive clinical data from the PARADIGM trial, a prospective, multicenter, single-arm study of 200 patients. Abbott said the study showed Amplatzer Paraclose is an effective, minimally invasive alternative to repeat open-heart surgery.

The company said in an email to MedTech Dive that it will present 30-day results from the trial at the upcoming Transcatheter Cardiovascular Therapeutics conference in San Diego. 

Amplatzer Paraclose is the latest addition to Abbott’s portfolio of minimally invasive Amplatzer devices, which includes the Piccolo Occluder for closing congenital heart defects and Talisman PFO Occluder for stroke risk reduction.

Outside of the U.S., the Amplatzer Paraclose PVL Occluder is known as the Amplatzer Valvular Plug III. The device has been approved to treat paravalvular leaks in Europe since 2020.

Abbott also makes the Amulet implant that seals the heart’s left atrial appendage to help reduce the risk of stroke in people with atrial fibrillation. A next-generation version of Amulet received Europe’s CE mark in August and is under FDA review.

来源:MedTech Dive 器械媒体 · medtechdive.com